Sinil Pharmaceutical Co. Ltd Cash Flow-to-Debt Ratio
Sinil Pharmaceutical Co. Ltd cash flow-to-debt ratio. Sinil Pharmaceutical Co. Ltd (012790) has a Cash Flow-to-Debt Ratio of 0.14x as of September 2025, meaning its operating cash flow of ₩2.62 Billion could theoretically repay 0% of its total liabilities (₩18.23 Billion) in one year. Check Sinil Pharmaceutical Co. Ltd earnings quality ratio to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Sinil Pharmaceutical Co. Ltd (2014–2024)
Cash flow-to-debt ratio of Sinil Pharmaceutical Co. Ltd from 2014 to 2024. Historical debt coverage capacity for Sinil Pharmaceutical Co. Ltd across 11 annual periods. Check 012790 capex plus investments ratio to assess the company's total reinvestment commitment from operating cash flow.
Sinil Pharmaceutical Co. Ltd Cash Flow-to-Debt Ratio by Year (2014–2024)
Sinil Pharmaceutical Co. Ltd cash flow-to-debt ratio by year from 2014 to 2024. Year-by-year debt coverage analysis for Sinil Pharmaceutical Co. Ltd. For the full cash flow conversion analysis, see how efficiently does Sinil Pharmaceutical Co. Ltd generate cash.
| Year | CF-to-Debt Ratio | Operating CF (KRW) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | 1.17x | ₩22.69 Billion | ₩19.36 Billion | ▲ +35.9% |
| 2023 | 0.86x | ₩15.15 Billion | ₩17.56 Billion | ▲ +23.3% |
| 2022 | 0.70x | ₩13.69 Billion | ₩19.55 Billion | ▼ -1.1% |
| 2021 | 0.71x | ₩11.16 Billion | ₩15.78 Billion | ▲ +10.8% |
| 2020 | 0.64x | ₩11.06 Billion | ₩17.33 Billion | ▼ -13.9% |
| 2019 | 0.74x | ₩12.31 Billion | ₩16.59 Billion | ▼ -9.5% |
| 2018 | 0.82x | ₩9.19 Billion | ₩11.22 Billion | ▲ +9.5% |
| 2017 | 0.75x | ₩8.67 Billion | ₩11.59 Billion | ▼ -32.8% |
| 2016 | 1.11x | ₩12.09 Billion | ₩10.86 Billion | ▲ +5.8% |
| 2015 | 1.05x | ₩9.56 Billion | ₩9.09 Billion | ▲ +2.1% |
| 2014 | 1.03x | ₩9.33 Billion | ₩9.06 Billion | — |